Mumbai: Cipla has announced that Cipla (EU) Limited, UK, a wholly owned subsidiary of the Company, has incorporated a new wholly owned subsidiary named 'CiplaRna GmbH' in Germany.
The new entity was officially established on May 28, 2025, with the objective of establishing a laboratory for mRNA-based formulation and drug development support.
The company clarified that Cipla (EU) Limited has subscribed 25,000 shares of EUR 1 each at par.
"CiplaRna is a related party. None of the promoters / promoter group / group companies have any interest in CiplaRna," Cipla stated in a BSE filing.
CiplaRna GmbH will operate within the pharmaceutical industry.
Read also: Cipla arm to acquire 26% stake in AMPIN Energy C&I Eighteen
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.
Read also: New Role Alert: Amit Patel named Head - Consumer Marketing Excellence, Cipla India Rx
